Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.

@article{Kusunoki2012TelmisartanER,
  title={Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.},
  author={Hiroshi Kusunoki and Yoshiaki Taniyama and Junya Azuma and Kazuma Iekushi and Fumihiro Sanada and Rei Otsu and Masaaki Iwabayashi and Keita Okayama and Hiromi Rakugi and Ryuichi Morishita},
  journal={Hypertension},
  year={2012},
  volume={59 2},
  pages={308-16}
}
Angiotensin (Ang) II type 1 receptor blockers have demonstrated beneficial effects beyond blood pressure control in the treatment of chronic kidney disease. There is clinical evidence that telmisartan is more effective than losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, because it is a partial agonist of peroxisome-proliferator activated receptor-γ (PPARγ), as well as an Ang II type 1 receptor blocker (AMADEO Study [A comparison of telMisartan versus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

The emerging role of hepatocyte growth factor in renal diseases.

Journal of receptor and signal transduction research • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis.

Circulation journal : official journal of the Japanese Circulation Society • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…